DrugId:  1
1. Name:  Beclanorsen
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in leukemia (lymphoid).
DrugId:  2
1. Name:  AGS-005
2. Groups:  Investigational
3. Description:  AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
4. Indication:  Investigated for use/treatment in leukemia (lymphoid).
DrugId:  3
1. Name:  XL228
2. Groups:  Investigational
3. Description:  XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
4. Indication:  Investigated for use/treatment in leukemia (lymphoid) and leukemia (myeloid).
DrugId:  4
1. Name:  IDM-4
2. Groups:  Investigational
3. Description:  IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes. Trials of this drug have most likely been discontinued by the manufacturer.
4. Indication:  Investigated for use/treatment in leukemia (lymphoid).
DrugId:  5
1. Name:  Lucatumumab
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
DrugId:  6
1. Name:  Apolizumab
2. Groups:  Investigational
3. Description:  Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.
4. Indication:  Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
DrugId:  7
1. Name:  OSI-461
2. Groups:  Investigational
3. Description:  OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
4. Indication:  Investigated for use/treatment in crohn's disease, inflammatory bowel disease, kidney cancer, leukemia (lymphoid), and prostate cancer.
DrugId:  8
1. Name:  Grn163l
2. Groups:  Investigational
3. Description:  GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the its potential utility in the treatment of patients with hematologic and solid tumor malignancies.
4. Indication:  Investigated for use/treatment in leukemia (lymphoid) and solid tumors.
DrugId:  9
1. Name:  Lumiliximab
2. Groups:  Investigational
3. Description:  Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.
4. Indication:  Investigated for use/treatment in asthma and leukemia (lymphoid).
DrugId:  10
1. Name:  Epratuzumab
2. Groups:  Investigational
3. Description:  Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monotclonal antibody, LL2 (EPB-2). Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).
4. Indication:  Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
DrugId:  11
1. Name:  Atacicept
2. Groups:  Investigational
3. Description:  Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.
4. Indication:  Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
DrugId:  12
1. Name:  Natural alpha interferon
2. Groups:  Approved, Investigational
3. Description:  Natural interferon alpha or Multiferon is obtained from the leukocyte fraction of human blood following induction with Sendai virus. Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography. Interferon alpha proteins are mainly involved in innate immune response against viral infection. They come in 13 subtypes that are called IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21. Multiferon consists of the 6 major subtypes are IFN-α1, IFN-α2, IFN-α8, IFN-α10, IFN-α14 and IFN-α21. Of these, IFN-α2 and IFN-α14 are glycosylated.
4. Indication:  Investigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
DrugId:  13
1. Name:  Talotrexin
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in solid tumors, lung cancer, leukemia (unspecified), and leukemia (lymphoid).
DrugId:  14
1. Name:  Forodesine
2. Groups:  Investigational
3. Description:  Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic leukemia and cutaneous T-cell lymphoma. Additional preliminary findings support its use for the management of some B-cell malignancies.
4. Indication:  Investigated for use/treatment in lymphoma (non-hodgkin's) and leukemia (lymphoid).
DrugId:  15
1. Name:  Seliciclib
2. Groups:  Investigational
3. Description:  R-roscovitine (Seliciclib or CYC202) is a trial drug in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel. Seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.
4. Indication:  Investigated for use/treatment in breast cancer, lung cancer, lymphoma (unspecified), multiple myeloma, leukemia (lymphoid), and cancer/tumors (unspecified).
DrugId:  16
1. Name:  Laromustine
2. Groups:  Investigational
3. Description:  VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
4. Indication:  Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), colorectal cancer, leukemia (lymphoid), leukemia (myeloid), lung cancer, myelodysplastic syndrome, pediatric indications, and solid tumors.
DrugId:  17
1. Name:  Sapacitabine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in solid tumors, cutaneous t-cell lymphoma, myelodysplastic syndrome, and leukemia (lymphoid).
DrugId:  18
1. Name:  AN-9
2. Groups:  Investigational
3. Description:  Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. It shows greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in preclinical studies.
4. Indication:  Investigated for use/treatment in liver cancer, lung cancer, melanoma, and leukemia (lymphoid).
DrugId:  19
1. Name:  Talabostat
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), lung cancer, melanoma, and pancreatic cancer.
DrugId:  20
1. Name:  Quarfloxin
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in leukemia (lymphoid).
DrugId:  21
1. Name:  Pentostatin
2. Groups:  Approved, Investigational
3. Description:  A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. [PubChem]
4. Indication:  For the treatment of hairy cell leukaemia refractory to alpha interferon.
DrugId:  22
1. Name:  Dasatinib
2. Groups:  Approved, Investigational
3. Description:  Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
4. Indication:  For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
DrugId:  23
1. Name:  Noscapine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), cancer/tumors (unspecified), and multiple myeloma.
DrugId:  24
1. Name:  Alvocidib
2. Groups:  Experimental, Investigational
3. Description:  Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
4. Indication:  Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
DrugId:  25
1. Name:  Navitoclax
2. Groups:  Investigational
3. Description:  Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others.Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying.
4. Indication:  Not Available
